Endocrinology

Type 2 diabetes management in China

Comprehensive T2DM care at Class A endocrinology departments — GLP-1, SGLT2 inhibitors, modern insulins, structured education, and integration with cardiometabolic and renal screening.

← All conditions

Overview

Type 2 diabetes affects approximately 140 million adults in China alone — one of the highest national totals globally. Class A endocrinology departments at academic centres run integrated programmes that combine GLP-1 receptor agonists, SGLT2 inhibitors, modern insulins, and structured cardiometabolic / renal monitoring at substantially lower cost than US/EU equivalents.

Modern T2DM care has moved beyond glycaemic control alone — the priority is reducing cardiovascular and renal risk, and many GLP-1 / SGLT2 agents have proven outcomes data for those endpoints.

Common symptoms

  • Often asymptomatic in early stages — many cases diagnosed incidentally on routine screening
  • Polyuria, polydipsia, blurred vision, recurrent infections in established disease
  • Fatigue, weight changes, slow wound healing
  • Numbness or tingling in hands / feet (neuropathy in long-standing disease)

Risk factors

  • BMI ≥ 25 (or ≥ 23 in Asian populations)
  • Family history of T2DM
  • Sedentary lifestyle
  • History of gestational diabetes
  • Hypertension, dyslipidaemia, PCOS
  • Age over 45

Standard diagnostic workup

Cost band at Class A international department: USD 140220 all-in.

  • Fasting glucose + HbA1c
  • Oral glucose tolerance test (OGTT) when HbA1c is borderline
  • Lipid panel, ALT/AST, eGFR, urine albumin/creatinine ratio
  • Comprehensive cardiovascular risk assessment
  • Diabetic eye examination at diagnosis (retinal screen)
  • Foot examination and neuropathy screening

Treatment options

First-line

Metformin

First-line for most patients without contraindication. Generic, very inexpensive.

First-line

GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide)

Strong glycaemic and weight benefits, cardiovascular outcome benefits in dedicated trials. China price 60–80% below US private pay.

Details →

First-line

SGLT2 inhibitors (empagliflozin, dapagliflozin)

Cardiorenal protection in addition to glycaemic effect. Particularly relevant for patients with CKD or heart failure.

First-line

Structured education + lifestyle programme

Foundational. Available as group programmes at Class A centres.

Second-line

DPP-4 inhibitors

Weight-neutral, well-tolerated. Modest A1c effect.

Second-line

Modern basal / basal-bolus insulin

Insulin glargine, degludec, lispro, aspart — all available at substantially lower cost.

Frequently asked

What's my 10-year risk of developing diabetes?
Take our FINDRISC self-test for a validated 8-item risk score recognised by the International Diabetes Federation.
What does T2DM workup cost in China?
Endocrinology consult + comprehensive metabolic + lipid + renal panel + initial foot/eye screening: USD 140–220 at a Class A international department, vs USD 600–1,200 US private.
Are modern insulins cheaper in China?
Yes. Insulin glargine biosimilars are USD 15–30 per vial vs USD 100+ US private pay. Modern rapid-acting analogues (lispro, aspart) similarly priced. Insulin pump and CGM access is available with appropriate prescribing.
What about diabetes remission with bariatric surgery?
Bariatric surgery (especially RYGB and SADI) drives durable T2DM remission in 65–80% of eligible patients with BMI ≥ 35. See bariatric procedures.

Talk to a senior physician

Free 30-minute video consult to review your case. We'll quote a workup and treatment plan at a Class A partner hospital — no commitment.

Book free consult